1,092 results

#105530-rh10

Ready-to-use AAV rh10 (similar to AAV10) particles produced from pAAV.CMV.PI.EGFP.WPRE.bGH (#105530). In addition to the viral particles, you will also receive purified pAAV.CMV.PI.EGFP.WPRE.bGH plasmid DNA. CMV-driven EGFP control. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

June 29, 2018

Academic Institutions and Nonprofits only

#105541-AAV1

Ready-to-use AAV1 particles produced from pENN.AAV.CamKII0.4.eGFP.WPRE.rBG (#105541). In addition to the viral particles, you will also receive purified pENN.AAV.CamKII0.4.eGFP.WPRE.rBG plasmid DNA. Expression of EGFP from CamKII promoter. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

Aug. 9, 2018

Academic Institutions and Nonprofits only

#100841-AAV1

Ready-to-use AAV1 particles produced from pAAV.Syn.GCaMP6m.WPRE.SV40 (#100841). In addition to the viral particles, you will also receive purified pAAV.Syn.GCaMP6m.WPRE.SV40 plasmid DNA. Syn-driven GCaMP6m calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Chen et al Nature. 2013 Jul 18;499(7458):295-300. d

March 16, 2018

Academic Institutions and Nonprofits only

#79871-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO_EGFP-GFE3 (#79871). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO_EGFP-GFE3 plasmid DNA. EF1a-driven, Cre-dependent expression of GFP-GFE3. These AAV preparations are suitable purity for injection into animals.

Don Arnold

Gross et al Nat Methods. 2016 Jun 6. doi: 10.1038/nm

Nov. 13, 2025

Academic Institutions and Nonprofits only

#214858-PHPeB

Ready-to-use AAV PHP.eB particles produced from AiP14496: pAAV-AiE0873m_3xC2-minBG-SYFP2-P2A-3XFLAG-10aa-H2B-WPRE3-BGHpA (Alias: CN4496) (#214858). In addition to the viral particles, you will also receive purified AiP14496: pAAV-AiE0873m_3xC2-minBG-SYFP2-P2A-3XFLAG-10aa-H2B-WPRE3-BGHpA (Alias: CN4496) plasmid DNA. minBG-driven expression of SYFP2 plus a separate nuclear FLAG epitope in striatal cholinergic neurons. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

Nov. 13, 2024

Academic Institutions and Nonprofits only

#112677-AAV1

Ready-to-use AAV1 particles produced from pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (#112677). In addition to the viral particles, you will also receive purified pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP plasmid DNA. EF1a-driven, Cre-dependent color switch. This AAV directs expression of nuclear mCherry in the absence of Cre. In the presence of Cre, nuclear EGFP (and not mCherry) will be expressed. These AAV preparations are suitable purity for injection into animals.

Brandon Harvey

Back et al Neuron. 2019 Feb 8. pii: S0896-6273(19)3

Dec. 2, 2019

Academic Institutions and Nonprofits only

#149415-AAV8

Ready-to-use AAV8 particles produced from pAAV-TBG-ER-TurboID (#149415). In addition to the viral particles, you will also receive purified pAAV-TBG-ER-TurboID plasmid DNA. TBG-driven expression of ER-localized TurboID (with HA and V5 tag). These AAV preparations are suitable purity for injection into animals.

Jonathan Long

Wei et al Nat Chem Biol. 2021 Mar;17(3):326-334. d

Aug. 6, 2025

Academic Institutions and Nonprofits only

#164510-AAV9

Ready-to-use AAV9 particles produced from pAAV.hSynap.(cyto)iGlucoSnFR-mRuby2 (#164510). In addition to the viral particles, you will also receive purified pAAV.hSynap.(cyto)iGlucoSnFR-mRuby2 plasmid DNA. Synapsin-driven, cytosolic-targeted iGlucoSnFR-mRuby2

Loren Looger

Keller et al Cell Rep. 2021 Jun 22;35(12):109284. doi

Nov. 29, 2021

Academic Institutions and Nonprofits only

#98930-AAV9

Ready-to-use AAV9 particles produced from pENN.AAV.GFAP.iGluSnFr.WPRE.SV40 (#98930). In addition to the viral particles, you will also receive purified pENN.AAV.GFAP.iGluSnFr.WPRE.SV40 plasmid DNA. GFAP-driven glutamate sensor. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2013 Feb;10(2):162-70. doi:

April 13, 2018

Academic Institutions and Nonprofits only

#99039-AAV1

Ready-to-use AAV1 particles produced from pAAV-CamKII-ArchT-GFP (PV2527) (#99039). In addition to the viral particles, you will also receive purified pAAV-CamKII-ArchT-GFP (PV2527) plasmid DNA. CaMKII-driven ArchT-GFP expression for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Han et al Front Syst Neurosci. 2011;5:18. Epub 201

Feb. 7, 2018

Academic Institutions and Nonprofits only

#137162-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-EYFP (#137162). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-EYFP plasmid DNA. EF1a-driven expression of EYFP in the presence of Cre (inhibited in the presence of Flp). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Feb. 2, 2021

Academic Institutions and Nonprofits only

#179460-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-DIO-JEDI-2P-WPRE (#179460). In addition to the viral particles, you will also receive purified pAAV-EF1a-DIO-JEDI-2P-WPRE plasmid DNA. EF1a-driven, Cre-dependent expression of voltage indicator JEDI-2P. These AAV preparations are suitable purity for injection into animals.

Francois St-Pierre

Liu et al Cell. 2022 Aug 16. pii: S0092-8674(22)00

Aug. 22, 2022

Academic Institutions and Nonprofits only

#50942-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn1-mRuby2-GSG-P2A-GCaMP6s-WPRE-pA (#50942). In addition to the viral particles, you will also receive purified pAAV-hSyn1-mRuby2-GSG-P2A-GCaMP6s-WPRE-pA plasmid DNA. GCaMP6s calcium sensor and bicistronic, physically separate mRuby2 expression under a human synapsin1 promoter. These AAV preparations are suitable purity for injection into animals.

Tobias Bonhoeffer, Mark Huebener, Tobias Rose

Rose et al Science. 2016 Jun 10;352(6291):1319-22.

March 7, 2018

Academic Institutions and Nonprofits only

#213814-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiSSTe10_dTomato_nlsdTomato (#213814). In addition to the viral particles, you will also receive purified pAAV_BiSSTe10_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the SST interneuron-targeting enhancer E10. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#99120-AAV1

Ready-to-use AAV1 particles produced from pAAV-ihSyn1-tTA (#99120). In addition to the viral particles, you will also receive purified pAAV-ihSyn1-tTA plasmid DNA. Expression of the tet-off transactivator from an inducible synapsin promoter. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Chan et al Nat Neurosci. 2017 Aug;20(8):1172-1179.

April 4, 2019

Academic Institutions and Nonprofits only

#137131-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Coff/Fon-BFP (#137131). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Coff/Fon-BFP plasmid DNA. EF1a-driven, Flp-dependent expression of BFP (inhibited in presence of Cre). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

April 5, 2021

Academic Institutions and Nonprofits only

#104492-AAVrg

Ready-to-use AAV Retrograde particles produced from pGP-AAV-syn-FLEX-jGCaMP7f-WPRE (#104492). In addition to the viral particles, you will also receive purified pGP-AAV-syn-FLEX-jGCaMP7f-WPRE plasmid DNA. Syn-driven, Cre-dependent GCaMP7f calcium sensor. These AAV preparations are suitable purity for injection into animals. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons.

Douglas Kim, GENIE Project

Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi

June 14, 2018

Academic Institutions and Nonprofits only

#179254-AAV1

Ready-to-use AAV1 particles produced from AAV-CAG-jGCaMP8f-WPRE (#179254). In addition to the viral particles, you will also receive purified AAV-CAG-jGCaMP8f-WPRE plasmid DNA. CAG-driven expression of calcium sensor GCaMP8f. These AAV preparations are suitable purity for injection into animals.

Loren Looger

May 18, 2023

Academic Institutions and Nonprofits only

#84445-AAV1

Ready-to-use AAV1 particles produced from pAAV-CAG-FLEX-rc [Jaws-KGC-GFP-ER2] (#84445). In addition to the viral particles, you will also receive purified pAAV-CAG-FLEX-rc [Jaws-KGC-GFP-ER2] plasmid DNA. CAG-driven, Cre-dependent Jaws-GFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chuong et al Nat Neurosci. 2014 Aug;17(8):1123-9. doi

Aug. 24, 2020

Academic Institutions and Nonprofits only

#100844-AAV1

Ready-to-use AAV1 particles produced from pAAV.CAG.GCaMP6s.WPRE.SV40 (#100844). In addition to the viral particles, you will also receive purified pAAV.CAG.GCaMP6s.WPRE.SV40 plasmid DNA. CAG-driven GCaMP6s calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Chen et al Nature. 2013 Jul 18;499(7458):295-300. d

March 16, 2018

Academic Institutions and Nonprofits only